• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    12/15/25 8:03:33 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIXC alert in real time by email
    false 0001460702 0001460702 2025-12-12 2025-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): December 12, 2025

     

    AIxCrypto Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37428   26-3474527
    (State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
    of incorporation)       Identification No.)

     

    5857 Owens Avenue, Suite 300    
    Carlsbad, California   90248
    (Address of principal executive offices)   (Zip Code)

     

    (760) 452-8111

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A common stock, par value $0.0001 per share   AIXC   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    On December 12, 2025, the Audit Committee of the Board of Directors of AIxCrypto Holdings, Inc., a corporation incorporated under the laws of the State of Delaware (the “Company”) terminated Macias Gini & O’Connell LLP (“MGO”) as the independent registered public accounting firm of the Company.

     

    During the Company’s two most recent fiscal years and the subsequent interim period through December 12, 2025, there were no disagreements with MGO on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of MGO, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report. During the Company’s two most recent fiscal years and the subsequent interim period through December 12, 2025, there were no reportable events of the type described in Item 304(a)(1)(v) of Regulation S-K.

     

    The Company provided MGO with a copy of the foregoing disclosure and requested MGO to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein. A copy of such letter furnished by MGO is filed as Exhibit 16.1 to this Form 8-K.

     

    On December 12, 2025, the Company’s Audit Committee approved the engagement of HTL International, LLC (“HTL”) as the Company’s new independent registered public accounting firm.

     

    During the Company’s two most recent fiscal years and the subsequent interim period through December [10], 2025, neither the Company nor anyone on its behalf consulted with HTL regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided that HTL concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and its related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K:

     

    No.   Description of Exhibits
    16.1   Letter from Macias Gini & O’Connell LLP
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      AIXCRYPTO HOLDINGS, INC.
       
    Date: December 15, 2025 By: /s/ Koti Meka
      Name: Koti Meka
      Title: Chief Financial Officer

     

    3

     

    Get the next $AIXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIXC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wang Jiawei claimed ownership of 1,658 shares (SEC Form 3)

    3 - AIxCrypto Holdings, Inc. (0001460702) (Issuer)

    12/5/25 7:46:10 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    SEC Filings

    View All

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    12/15/25 8:03:33 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by AIxCrypto Holdings Inc.

    DEF 14A - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    12/15/25 10:11:02 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by AIxCrypto Holdings Inc.

    EFFECT - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    12/12/25 12:15:14 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    YT Jia, Chief Advisor to AIxC Shares Weekly AIxC Investor Update: AIxC Appointed Andrew Grossman as Head of Legal Where he will Take Full Responsibility for the Company's Legal, Compliance, and Governance Framework

    Weekly report is now upgraded to the dual public Company structure weekly update and will report the progress of the Company's dual flywheel businesses every week.LOS ANGELES, Dec. 14, 2025 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or ", the Company", )) today shared a weekly business update from YT Jia, Chief Advisor of AIxC and Founder and Global Co-CEO of Faraday Future (NASDAQ:FFAI). "As I serve as Chief Advisor to AIxC, with the Company's day-to-day operations led by its executive management team, I will continue to report the progress of the Company's Dual F

    12/14/25 11:44:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its "Three Driving Forces" Strategy to Become the No.1 Gateway to AI Web3 and a Bridge Between Web2 and Web3

    The FFAI + AIXC "dual flywheel, dual bridge, dual listing" framework has now been fully established, ushering in a new era of high-speed, two-way empowerment between EAI and Crypto. This approach delivers transformative Web3 value to Web2 while also bringing substantial off-chain Web2 growth into Web3. Breaking boundaries and fostering integration—rather than operating in isolation—is the true future of the Web3 industry.AIxCrypto (AIXC) is now focused on its new "Three Driving Forces" strategy, aimed at becoming the No.1 gateway into the AI Web3 world:BesTrade DeAI Agent & Web3 AI Terminal – the No.1 entry point for Web3 trading, integrating intelligent AI agents with user-facing trading in

    11/20/25 12:36:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care